Drugs / Intravenous hyperimmune immunoglobulin
Intravenous hyperimmune immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02287467 | Jan 2015 → Jun 2018 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous hyperimmune immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02287467 ↗ |
| Known as | Flu-IVIG | “The INSIGHT 006 trial administered anti-influenza hyperimmune intravenous immunoglobulin (Flu-IVIG) to patients hospitalized with influenza.” PMID 37289541 ↗ Jul 2023 |
| Known as | IVIG | “Intravenous hyperimmune immunoglobulin (IVIG)” NCT02287467 ↗ |
| Modality | Protein / enzyme biologic | “The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are...” NCT02287467 ↗ |
| Route | Intravenous | “Administered intravenously (IV) at a dose of 0.25 g/kg” NCT02287467 ↗ |